background
major
trigger
asthma
exacerb
infect
respiratori
viru
commonli
rhinoviru
type
inflamm
known
associ
increas
risk
exacerb
gener
whether
type
inflamm
baselin
increas
risk
futur
virusinduc
exacerb
unknown
object
assess
whether
type
inflamm
associ
increas
risk
virusinduc
exacerb
asthma
method
stabl
asthmat
spirometri
skin
prick
test
measur
feno
sputum
induc
differenti
cell
count
patient
follow
month
assess
research
unit
symptom
exacerb
nasal
swab
collect
assess
underw
viral
detect
pcr
result
total
asthma
patient
recruit
experienc
exacerb
followup
period
respiratori
viru
detect
exacerb
sputum
eosinophil
baselin
increas
risk
subsequ
virusinduc
exacerb
hr
ci
feno
ppb
hr
ci
establish
type
inflamm
stabl
diseas
risk
factor
virusinduc
exacerb
reallif
set
measur
type
inflamm
sputum
eosinophil
feno
could
includ
risk
assess
patient
asthma
futur
studi
viral
infect
asthmat
individu
alarmin
stimul
helper
cell
innat
lymphoid
cell
produc
caus
recruit
eosinophil
airway
increas
mucu
secret
bronchial
hyperreact
class
switch
bcell
produc
ige
whether
eosinophil
inflamm
also
risk
factor
virusinduc
exacerb
unknown
demonstr
virus
activ
eosinophil
directli
signal
toll
like
receptor
result
propag
inflamm
reduc
rate
exacerb
whether
effect
predominantli
relat
viru
induc
nonvir
exacerb
unknown
adjust
inhal
corticosteroid
ic
treatment
base
maintain
low
airway
eosinophil
effect
symptom
base
manag
reduc
exacerb
frequenc
induct
process
sputum
feasibl
clinic
set
fraction
exhal
nitric
oxid
feno
produc
airway
epitheli
cell
stimul
associ
increas
risk
exacerb
treatment
strategi
base
feno
reduc
rate
exacerb
show
conflict
result
trial
antibodi
shown
reduct
exacerb
rate
patient
high
periostin
protein
induc
receiv
treatment
ic
poor
asthma
control
knowledg
studi
evalu
associ
feno
sputum
eosinophil
risk
virusinduc
exacerb
specif
hypothesis
high
type
inflammatori
biomark
would
associ
higher
risk
virusinduc
asthma
exacerb
test
conduct
observ
prospect
cohort
studi
heterogen
popul
asthmat
examin
patient
baselin
subsequ
exacerb
th
od
stabl
asthma
patient
recruit
period
may
decemb
respiratori
outpati
clinic
bispebjerg
univers
hospit
copenhagen
denmark
patient
follow
least
month
specialist
outpati
clinic
enrol
studi
patient
examin
describ
follow
month
entri
date
time
patient
instruct
contact
studi
team
experienc
worsen
asthma
symptom
increas
use
surpass
usual
daytoday
variat
patient
examin
asthma
inflammatori
diseas
airway
characteris
variabl
airflow
obstruct
hyperrespons
one
frequent
chronic
diseas
young
adult
acut
exacerb
main
caus
morbid
healthcar
utilis
thu
prevent
futur
exacerb
key
goal
clinic
manag
patient
asthma
infect
respiratori
virus
particularli
rhinovirus
rv
common
trigger
asthma
exacerb
mechan
still
unclear
airway
epitheli
cell
cultur
ex
vivo
nonasthmat
subject
produc
tslp
respons
within
hour
contact
studi
team
exacerb
defin
increas
symptom
requir
chang
medic
judg
attend
physician
line
atser
recommend
exacerb
manag
adjust
inhal
therapi
record
mildmoder
wherea
exacerb
requir
cours
oral
corticosteroid
oc
admiss
hospit
consid
sever
addit
patient
instruct
perform
nasal
swab
home
experienc
symptom
common
coldpati
examin
occas
local
scientif
ethic
committe
approv
studi
journal
nr
subject
inform
gave
written
consent
spirometri
easyon
ndd
switzerland
complet
accord
er
recommend
use
nhane
iii
refer
skin
prick
test
soluprick
alk
denmark
complet
atopi
defin
posit
test
maximum
wheal
diamet
mm
least
one
ten
common
aeroallergen
grass
hous
dust
mite
birch
mugwort
dog
cat
hors
cladosporum
herbarum
alternaria
tenui
fraction
expiratori
nitric
oxid
feno
analys
nioxminor
aerocrin
solna
sweden
follow
recommend
er
at
use
mean
two
measur
atsdefin
cutoff
ppb
feno
use
defin
patient
high
low
feno
sputum
induc
accord
er
guidelin
process
use
protocol
describ
pavord
et
al
differenti
cell
count
cytospin
obtain
nonsquam
cell
cutoff
sputum
eosinophil
appli
defin
high
low
sputum
eosinophil
report
correspond
percentil
sputum
eosinophil
healthi
adult
blood
sampl
assess
hospit
clinic
servic
includ
full
white
blood
cell
differenti
count
measur
creactiv
protein
crp
well
total
ige
coba
roch
basel
switzerland
asthma
control
assess
asthma
control
questionnair
acq
nasal
swab
copan
italia
use
sampl
nasal
fluid
test
use
tandem
multiplex
realtim
pcr
assay
detect
comprehens
rang
respiratori
virus
human
adenoviru
speci
bd
human
bocaviru
coronavirus
influenza
virus
b
c
parainfluenza
virus
ki
wu
polyomavirus
respiratori
syncyti
viru
type
b
human
metapneumoviru
rv
detect
pcr
direct
sequenc
utr
genom
rv
product
identifi
speci
level
rva
rvb
rvc
sequenc
bp
product
align
known
rv
sequenc
use
clustalx
softwar
data
analys
spss
version
ibm
spss
armonk
ny
usa
normal
distribut
data
report
meanaestandard
deviat
analys
use
student
test
continu
variabl
chisquar
test
categor
variabl
logtransform
variabl
report
geometr
mean
gm
ci
nonnorm
distribut
data
eg
cell
count
report
median
rang
comparison
made
use
kruskalw
test
assess
abil
baselin
characterist
predict
risk
exacerb
proport
hazard
model
cox
regress
use
adjust
predefin
potenti
confound
exacerb
risk
includ
ic
dose
smoke
statu
acq
score
predict
forc
expiratori
volum
first
second
expir
baselin
inflammatori
marker
examin
feno
sputum
eosinophil
highli
correl
previou
studi
data
marker
test
separ
avoid
multicollinear
analys
pvalu
consid
signific
total
patient
approach
patient
agre
particip
figur
ic
taken
patient
remain
use
short
act
alon
recruit
patient
feno
elev
baselin
ppb
among
patient
abl
produc
valid
sputum
sampl
patient
sputum
eosinophil
eight
patient
high
feno
high
sputum
eosinophil
clinic
characterist
studi
subject
describ
tabl
two
patient
treat
antibiot
suspect
bacteri
pneumonia
although
bacteri
cultur
later
found
neg
patient
characterist
includ
age
sex
smoke
statu
differ
exacerb
tabl
exacerb
group
mean
feno
baselin
higher
ppb
ci
compar
nonexacerb
group
ppb
ci
exacerb
patient
also
higher
acq
score
baselin
compar
nonexacerb
patient
trend
lower
preval
atopi
exacerb
group
vs
lung
function
ic
dose
sputum
blood
differenti
cell
count
similar
group
figur
proport
hazard
model
construct
adjust
known
determin
exacerb
risk
amount
ic
usag
current
smoke
acq
score
predict
baselin
demograph
variabl
sex
age
bmi
pvalu
univari
analys
includ
model
inflammatori
marker
assess
separ
predict
risk
exacerb
summaris
tabl
patient
virusneg
group
analysi
potenti
relev
risk
factor
relat
type
inflamm
also
examin
adjust
potenti
confound
atop
statu
blood
eosinophil
cellsl
total
ige
iu
none
variabl
predict
risk
exacerb
tabl
studi
feno
ppb
sputum
eosinophil
associ
increas
risk
develop
virusinduc
b
l
e
baselin
characterist
patient
develop
exacerb
followup
experi
exacerb
exacerb
pvalu
knowledg
first
studi
assess
type
airway
inflamm
risk
factor
specif
virusinduc
asthma
exacerb
synergist
effect
allerg
sensitis
viral
infect
risk
hospit
admiss
describ
children
studi
observ
increas
risk
exacerb
viral
nonvir
patient
sensitis
common
aeroallergen
indic
associ
might
pronounc
paediatr
popul
studi
found
crosslink
high
affin
igereceptor
result
blunt
interferon
respons
rv
turn
associ
ineffect
viral
clear
pronounc
asthma
symptom
furthermor
antiig
antibodi
omalizumab
shown
elimin
returntoschool
peak
exacerb
larg
cohort
asthmat
children
suggest
reduct
virusinduc
exacerb
taken
togeth
indic
high
ige
might
play
role
virusinduc
asthma
exacerb
howev
studi
high
ige
associ
increas
risk
virusinduc
exacerb
advent
antibodi
treatment
option
come
year
widespread
intent
enhanc
personalis
asthma
manag
tailor
medic
choic
dosag
accord
inflammatori
phenotyp
treatment
like
prevent
exacerb
given
respiratori
virus
major
trigger
exacerb
understand
pathway
airway
inflamm
influenc
risk
virusinduc
exacerb
critic
step
understand
optimis
use
antibodi
therapi
achiev
best
individu
patient
outcom
conclus
shown
high
feno
sputum
eosinophil
baselin
risk
factor
virusinduc
exacerb
reallif
set
confirm
larger
studi
could
implic
risk
assess
asthma
patient
studi
fund
bispebjerg
univers
hospit
univers
copenhagen
unrestrict
grant
lundbeck
foundat
